Summary:
In individuals with type 2 diabetes, flaxseed oil supplementation (FOS) significantly reduced platelet hyperaggregability compared to placebo (safflower oil supplementation), though it was associated with no other significant improvements in the cluster of seven metabolic and inflammatory risk factors, and no influence from apolipoprotein E genotype.
| PICO | Description |
|---|---|
| Population | Thirty-two adults with well-controlled type 2 diabetes participating in a double-blind, placebo-controlled study. |
| Intervention | Flaxseed oil supplementation (FOS) administered between study visits in a controlled clinical setting. |
| Comparison | Safflower oil supplementation (SOS) as placebo control. |
| Outcome | FOS resulted in a statistically significant reduction in platelet aggregability compared to SOS, with no significant effects on the remaining six parameters (abdominal obesity, hypertension, hyperglycemia, dyslipidemia, LDL oxidation, inflammation). Apolipoprotein E genotypes did not impact outcomes. |
Source: Barre, Douglas E., et al. “Thus far there are no statistically significant differences between various apolipoprotein E genotypes in the cluster of seven responsiveness to a flaxseed oil supplement in persons with type 2 diabetes.” Read article here.
